Respiratory pathogens in patients with acute exacerbation of non-cystic fibrosis bronchiectasis from a developing country

Medicine and Dentistry

• Antibiogram 16%
• Antibiotic Resistance 33%
• Antiinfective Agent 16%
• Bacterial Overgrowth 16%
• Bronchiectasis 100%
• Ceftazidime 16%
• Ciprofloxacin 33%
• Cross Sectional Study 16%
• Cystic Fibrosis 100%
• Haemophilus 33%
• Imipenem 16%
• Infection 16%
• Meticillin 16%
• Mucus 16%
• Pathogen 100%
• Piperacillin/Tazobactam 16%
• Pseudomonas aeruginosa 33%
• Reinfection 16%
• Respiratory Disease 16%
• Respiratory Medicine 33%
• Staphylococcus Aureus 33%
• Trimethoprim/Sulfamethoxazole 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibiotic Resistance 33%
• Antiinfective Agent 33%
• Antimicrobial Resistance 33%
• Bronchiectasis 100%
• Ceftazidime 16%
• Ciprofloxacin 33%
• Cotrimoxazole 16%
• Cross-Sectional Study 16%
• Cystic Fibrosis 100%
• Haemophilus 33%
• Imipenem 16%
• Infection 16%
• Infectious Agent 100%
• Inflammation 16%
• Meticillin 16%
• Piperacillin Plus Tazobactam 16%
• Pseudomonas aeruginosa 33%
• Reinfection 16%
• Respiratory Tract Disease 16%
• Staphylococcus Aureus 33%

Immunology and Microbiology

• Acute Bronchitis 25%
• Antibiotic Sensitivity 25%
• Antimicrobial Resistance 50%
• Bacterial Overgrowth 25%
• Haemophilus 50%
• Infectious Agent 100%
• Influenza 50%
• Pseudomonas aeruginosa 50%
• Pulmonary Inflammation 25%
• Staphylococcus Aureus 50%